You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR TRAVASOL 10% IN PLASTIC CONTAINER


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for TRAVASOL 10% IN PLASTIC CONTAINER

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00313807 ↗ Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage Withdrawn Queen's University Phase 2 2005-11-01 Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.
NCT02032953 ↗ Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Active, not recruiting Canadian Institutes of Health Research (CIHR) Phase 4 2013-12-01 The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗ Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Active, not recruiting McGill University Health Center Phase 4 2013-12-01 The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗ Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia Active, not recruiting McGill University Health Centre/Research Institute of the McGill University Health Centre Phase 4 2013-12-01 The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for TRAVASOL 10% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 10% IN PLASTIC CONTAINER
Intervention Trials
Contrast Nephropathy 1
Renal Failure 1
Colorectal Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for TRAVASOL 10% IN PLASTIC CONTAINER
Intervention Trials
Renal Insufficiency 1
Kidney Diseases 1
Colorectal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRAVASOL 10% IN PLASTIC CONTAINER

Trials by Country

Trials by Country for TRAVASOL 10% IN PLASTIC CONTAINER
Location Trials
Canada 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRAVASOL 10% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 10% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Phase 4 1
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for TRAVASOL 10% IN PLASTIC CONTAINER
Clinical Trial Phase Trials
Active, not recruiting 1
Withdrawn 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRAVASOL 10% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 10% IN PLASTIC CONTAINER
Sponsor Trials
Queen's University 1
Canadian Institutes of Health Research (CIHR) 1
McGill University Health Center 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for TRAVASOL 10% IN PLASTIC CONTAINER
Sponsor Trials
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.